QLife (QLIFE) Q1 2025 earnings summary

Executive summary

• Revenue reached KSEK 110 in Q1 2025, up from zero in Q1 2024, reflecting initial commercialization efforts.

• Net loss narrowed to KSEK -6,120 from KSEK -8,351 year-over-year, with significant cost reductions from organizational downsizing.

• Strategic shift from R&D to sales focus, with new product launches and regulatory progress in the UK and EU.

• Board expansion and new partnerships, including a letter of intent with a top-20 global pharma company, support commercialization.

• Cash position at quarter-end was KSEK 2,707, bolstered by a rights issue and new credit facility.

Financial highlights

• Revenue: KSEK 110 (Q1 2025) vs. KSEK 0 (Q1 2024); EBITDA: KSEK -5,269 vs. KSEK -11,716.

• Net loss: KSEK -6,120 vs. KSEK -8,351 year-over-year; EPS: SEK -0.73 vs. SEK -0.01.

• Cash flow: KSEK -8 vs. KSEK 2,714; cash and cash equivalents: KSEK 2,707 at March 31, 2025.

• Shareholders' equity: KSEK -367 at quarter-end, reflecting ongoing losses and capital measures.

• Operating expenses significantly reduced due to cost-saving measures and headcount reduction.

Outlook and guidance

• Focus on commercialization of Egoo systems, especially in women's health and chronic disease management.

• Ongoing clinical trials in the UK for PKU-related products, with regulatory submissions planned for Q4 2025.

• Anticipated introduction of additional biomarker tests and expansion into Hospital-at-Home initiatives in Scandinavia and the UK.

• Strategic partnerships and digital marketing to drive growth in target segments.